V+ GmbH & Co Fonds 2 KG, a German Venture Capital fund invests in Redbiotec. The investment strengthens the leading position of Redbiotec in designer virus-like particles (VLPs) and protein complexes. Solidly financed, Redbiotec is applying its unique CAP ® technology for the development of additional novel vaccine and biologic candidates.
